Tonix's Long COVID Drug Fails to Meet Midstage Trial Goal
Tonix Pharmaceuticals said on Tuesday its experimental drug failed to meet the primary goal in a midstage study for management of widespread muscle pain and tenderness associated with long COVID-19.
Reuters Health Information
source https://www.medscape.com/s/viewarticle/996097?src=rss
Reuters Health Information
source https://www.medscape.com/s/viewarticle/996097?src=rss
Comments
Post a Comment